louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06618066: Decision-making Preferences and Its Related Factors on Parents With Children Having Cancer
Official title: Decision-making Preferences and Its Related Factors on Parents With Children Having Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pediatric Cancer
Keywords: Decision making preferences
Parents
Coping behaviors
Family cohesion
Lead sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
Sponsor class: OTHER
First posted: 2024-10-01
Enrollment: 130
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: FAMILY_BASED
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study was conducted in the pediatric hematology-oncology ward and outpatient clinic of a medical center in southern Taiwan.

Brief summary: A cross-sectional correlational study was conducted in the pediatric hematology-oncology ward and outpatient clinic of a medical center in southern Taiwan. Participants included fathers or mothers of children diagnosed with cancer aged between 20 and 65 years. Structured questionnaires were used, including FACES IV, JCS, and CPS-P. This study aims to explore the current status of family cohesion, coping behaviors, and decision making preferences among parents of children with cancer, and to identify factors influencing decision making preferences.


Eligibility criteria: Inclusion Criteria:

1. Parents aged between 20 and 65 years whose child has been diagnosed with pediatric cancer by a physician.
2. Individuals who understand Mandarin or Taiwanese Hokkien and are able to complete the questionnaire.
3. Individuals who consent to participate in the study after being informed of the research purpose.

Exclusion Criteria:

(1)Individuals diagnosed with a mental illness by a physician.

Primary outcomes:
measure: Exploring the current state of decision-making preferences among parents of children with cancer using the Control Preferences Scale for Pediatrics (CPS-P)
timeFrame: Single point in time: At enrollment
measure: Exploring the current state of family cohesion among parents of children with cancer using the Family Adaptability and Cohesion Evaluation Scale (FACES)
timeFrame: Single point in time: At enrollment
measure: Exploring the current coping behaviors of parents of children with cancer using the Jalowiec Coping Scale (JCS)
timeFrame: Single point in time: At enrollment
Secondary outcomes:
Other outcomes:
Locations:
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Medical University
Study officials:
affiliation: Kaohsiung Medical University
name: Li-Min Wu, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Olson D. FACES IV and the Circumplex Model: validation study. J Marital Fam Ther. 2011 Jan;37(1):64-80. doi: 10.1111/j.1752-0606.2009.00175.x.
citation: Degner LF, Sloan JA, Venkatesh P. The Control Preferences Scale. Can J Nurs Res. 1997 Fall;29(3):21-43.
citation: Jalowiec A, Murphy SP, Powers MJ. Psychometric assessment of the Jalowiec Coping Scale. Nurs Res. 1984 May-Jun;33(3):157-61.
Clinical trial NCT04800666: Effect of Stellate Ganglion Block Combined With Facial Nerve Block on the Treatment of Idiopathic Facial Paralysis
Official title: Effect of Stellate Ganglion Block Combined With Facial Nerve Block on the Treatment of Idiopathic Facial Paralysis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Peripheral Facial Palsy
Keywords: Peripheral Facial Palsy
Stellate Ganglion Block
Facial Nerve Block
Lead sponsor: Yangzhou University
Sponsor class: OTHER
First posted: 2021-03-16
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Peripheral facial palsy is caused by damage to the facial nerve at any site of the peripheral branches after the facial nucleus.Stellate ganglion block is performed to treat peripheral facial palsy because it increases blood flow and promotes nerve regeneration.Facial Nerve Block worked with elimination of local inflammation of nerve and oppression. Facial nerve block is a treatment that inject drugs into the damaged nerve around to eliminate local inflammation and compression of the nerve.


Eligibility criteria: Inclusion Criteria:

Diagnosed by clinical and neurological assessment as one-sided simple facial

* Age 18 to 75 years
* HBGS above Ⅳ
* the course of IFP not over 7 days.

Exclusion Criteria:

* Coagulation dysfunction
* plate plate plate shape, quantity or abnormal function
* mental system diseases
* Gillan-Bahrain syndrome
* cancer, mumps, shingles infection, jaw facial pus lymph nodeitis, encephalitis, -cerebral hemorrhage and other diseases
* local infection or systemic infectious disease at the puncture site
* can not accept to nerve block

Primary outcomes:
measure: Change from Baseline House-Brackmann
timeFrame: Baseline ,change from baseline House-Brackmann at 3 days,6 days,9 days,14 days,one month,two month
measure: Change from Baseline Sunnybrook
timeFrame: Baseline,change from baseline Sunnybrook at 3 days,6 days,9 days,14 days, one month,two month
Secondary outcomes:
Other outcomes:
Locations:
city: Yangzhou
country: China
facility: the Affiliated Hospital of Yangzhou University
state: Jiangsu
Study officials:
affiliation: The Affiliated Hospital of Yangzhou University
name: zhuan zhang, professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04151966: Myocardial Injury Following Elective Direct Current Cardioversion for Atrial Arrhythmias
Official title: Evaluation of Potential Myocardial Injury Following Elective Direct Current Cardioversion for Atrial Arrhythmias
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cardioversion
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2019-11-05
Enrollment: 104
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult male and females age 18 and above identified from the electronic medical record (EMR) calendar of patients scheduled for an elective direct current cardioversion.

Brief summary: Researchers are trying to determine if heart injury occurs in subjects who undergo direct current cardioversion.

Detailed description: External transthoracic direct current (DC) cardioversion is a commonly used method of terminating cardiac arrhythmias. Conventional wisdom indicates that external DC cardioversion causes myocardial injury. Previous research has shown that DC cardioversion resulted in myocardial injury as evidenced by increased levels of cardiac troponin, even though those changes were modest. Many of these studies evaluated monophasic defibrillators and older, less sensitive cardiac troponin assays. The current standard is now to use modern biphasic defibrillators and new high sensitivity cardiac troponin assays (hs-cTnT). It is conceivable that the newer defibrillators may not cause myocardial injury. It would be important to understand if myocardial injury occurs in this setting and its approximate magnitude as it would the interpretation of hs-cTnT values in patients and therefore influenced diagnoses. It may be if a threshold energy level can be identified that is would also influence the choice of energy used to deliver the shock in this situation.

A previous preliminary study documented no evidence of myocardial injury after elective DC cardioversion with modern day defibrillators. We aim to validate and expand that study here at Mayo Clinic Rochester.

Eligibility criteria: Inclusion Criteria:

* Patients who are undergoing elective direct current cardioversion, either externally or via the patient's internal cardioverter-defibrillator

Exclusion Criteria:

* Patients under age 18
* Patients with myocardial infarction, coronary artery bypass grafting or any invasive cardiac procedure in the previous six weeks
* Pregnant patients
* Patients who cannot provide informed consent because of cognitive dysfunction

Primary outcomes:
measure: Myocardial injury
timeFrame: Baseline, 6-24 hours post procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Allan S Jaffe, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00955565: Accuracy of Navigation in Placement of Sacroiliac Screw
Official title: Accuracy of Navigation in Placement of Sacroiliac Screw. Multicenter Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hip Fracture
Lead sponsor: AO Innovation Translation Center
Sponsor class: OTHER
First posted: 2009-08-10
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the precision of computer-assisted navigation for hip screw implantation to conventional fixation without navigation.

Detailed description: Standard treatment for sacroiliac dislocations and sacroiliac fractures is placement of two screws through the iliosacral joint into the sacral ala or the body of the S1 vertebra. Correct positioning is technically demanding. Screw displacement may reduce the strength of fixation and lead to neurological complications.

Secondary objectives of the study are to compare the fluoroscopy time, complications and surgery duration between the treatments.

Eligibility criteria: Inclusion Criteria:

* Radiologically confirmed sacroiliac dislocation or sacroiliac fracture
* Sacroiliac arthritis
* Age 18 years and more
* Written informed consent by patient or his/her legal representative

Exclusion Criteria:

* Poor life expectancy (\<3months)
* Fracture of pathologic origin
* History of substance abuse (recreational drugs, alcohol)within 12 months prior to screening
* Prisoner
* Currently involved in another study that precludes or complicates participation
* Disease or condition that would preclude accurate evaluation (e.g., significant psychiatric disease)

Primary outcomes:
measure: Proportion of misplaced sacroiliac screws as evaluated by postop CT-scanning.
timeFrame: 2 days
Secondary outcomes:
measure: Fluoroscopic time, complications and surgery duration.
timeFrame: 2 days
Other outcomes:
Locations:
city: Charlottesville
country: United States
facility: University of Virginia Health System
state: Virginia
city: Berlin
country: Germany
facility: Charité Berlin, Campus Virchow Klinikum
city: Hannover
country: Germany
facility: Medizinische Hochschule Hannover
city: Homburg
country: Germany
facility: Universitätsklinikum des Saarlandes
city: München
country: Germany
facility: Klinikum rechts der Isar der TU München
city: Münster
country: Germany
facility: Universitätsklinikum Münster
city: Stuttgart
country: Germany
facility: Katharinenhospital
city: Ulm
country: Germany
facility: Universität Ulm
city: Dubai
country: United Arab Emirates
facility: Rashid Hospital
Study officials:
affiliation: AO Clinical Investigation and Documentation, Davos, Switzerland
name: Beate P. Hanson, MD
role: STUDY_DIRECTOR
affiliation: Klinikum rechts der Isar der TU München
name: Ulrich C. Stöckle, Prof. MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02932865: Modern Analyses of the Semen in Evaluating Male Fertility and Treatment Options of Male Infertility
Official title: Modern Analyses of the Semen in Evaluating Male Fertility and Treatment Options of Male Infertility
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infertility, Male
Keywords: azoospermia
male fertility
MD-TESE
miRNA
piRNA
male infertility
Lead sponsor: Turku University Hospital
Sponsor class: OTHER_GOV
Collaborators: name: Lund University Hospital
name: University of Turku
First posted: 2016-10-13
Enrollment: 120
Sex: MALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Men contacting the fertility clinic in Turku University Hospital

Brief summary: Men are recruited to collect seminal plasma samples and serum samples from men with azoospermia, men receiving medical treatment of infertility and men attending semen analysis. MicroRNA (miRNA) and PiWi-interacting RNA (piRNA) are analyzed for all of the groups to find potential differences. Steroid hormones are analyzed by liquid chromatography-tandem mass spectrometry.

Detailed description: Azoospermic men attending microdissection testicular sperm extraction (MD-TESE) are group A. Second group (B) is the men with poor semen quality, who are treated with aromatase inhibitor, antiestrogen or human choriogonadotropic hormone (HCG) to improve semen quality. Third group (C) consists of men submitting semen analysis. The intended number of participants is 60, 60 and 100 men, respectively.

Seminal plasma and serum samples are collected and miRNA and piRNA are analyzed. Steroid hormones are analyzed by liquid chromatography-tandem mass spectrometry. The participants are given a physical examination and testicular ultrasound. The primary aim of this study is to develop a tool to better estimate the sperm recovery rate (SRR) of azoospermic men scheduled for MD-TESE. Since no data have been published presenting miRNA and piRNA levels in men with normal semen, a secondary aim is to describe the levels of miRNA and piRNA in unselected men. Third part of this study aims to find if medical treatment improving semen parameters affects miRNA ja piRNA findings.

Eligibility criteria: Inclusion Criteria:

* Ability to produce semen sample

Exclusion Criteria:

* Cognitive impairment
* Inadequate language skills for informed consent

Primary outcomes:
measure: miRNA and piRNA according to sperm recovery in MD-TESE
timeFrame: Two years
Secondary outcomes:
measure: Assess miRNA and pRNA changes with hormonal treatment
timeFrame: two years
Other outcomes:
measure: Describe miRNA and piRNa levels in seminal plasma of unselected men
timeFrame: two years
Locations:
city: Turku
country: Finland
facility: Turku University Hospital
Study officials:
affiliation: University of Turku
name: Antti Perheentupa, MD,PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03897465: Lomatuell Pro® Versus UrgoTul® in the Management of Acute Wounds
Official title: Comparative Evaluation of the propertieS of the Contact LAyer Dressing LOMatuell Pro® Versus UrgoTul® in the Management of Acute Wounds
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Wounds
Lead sponsor: Lohmann & Rauscher
Sponsor class: INDUSTRY
Collaborators: name: RCTs
First posted: 2019-04-01
Enrollment: 183
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Comparative evaluation of the propertieS of the contact LAyer dressing LOMatuell Pro® versus UrgoTul® in the management of acute wounds

Detailed description: National, multicenter, prospective, randomized in parallel groups, non-inferiority, open-label investigation study.

Eligibility criteria: Inclusion Criteria:

* Acute wound: traumatic wound (dermabrasion, skin tears, other), small burns 1st and 2nd degree requiring the use of dressings
* Acute wound size between 3 cm² and 24 cm² (wound could be covered by 2 investigational products maximum)
* Wound whose duration is ≤ 3 days
* Both gender with an age ≥ 18 years
* Written confirmation from the study nurse that the patient was informed, orally agreed to participate and to comply with study treatment and planned visits
* Subject able to follow the protocol

Exclusion Criteria:

* Chronic and acute surgical wound
* Infected, moderately to strongly exudative and haemorrhagic wound
* Diagnosed underlying disease (e.g. diabetic neuropathy, stroke, etc.) which as judged by the investigator could interfere with the pain assessment
* Known allergy/hypersensitivity to any of the components of the investigational products
* Participation in other clinical investigation within one month prior to start of investigation
* Pregnant or breast-feeding women
* Person protected by a legal regime (tutorship or guardianship)
* Patients unable to manifest an oral consent to participate (e.g. dementia) or to understand the use of the VAS (visual analogue scale) tool
* Patient not covered by health insurance/social security

Primary outcomes:
measure: Percentage of Wound Dressing Changes Associated With a Pain <30 mm on Visual Analog Scale (VAS)
timeFrame: At Visit 2 (Day 3 ± 2 days)
Secondary outcomes:
measure: Complete Healing
timeFrame: At Visit 3 (Day 21 or earlier, as soon as the wound is epithelialized)
Other outcomes:
Locations:
city: Limonest
country: France
facility: CICA+
Study officials:
affiliation: Lohmann & Rauscher
name: Daria TROFIMENKO
role: STUDY_DIRECTOR
References:
Clinical trial NCT02405065: Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573
Official title: Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573 in Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Neoplasms
Lead sponsor: Hanmi Pharmaceutical Company Limited
Sponsor class: INDUSTRY
First posted: 2015-04-01
Enrollment: 72
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The main objective of this study is to determine the maximum tolerated dose (MTD) and recommended phase 2 dose of HM95573.

Detailed description: Besides the main objective, there are 3 other objectives as follows:

* To evaluate the anti-cancer effect of HM95573 in solid tumor patients
* To investigate the pharmacokinetic profile of HM95573 after oral administration.
* To investigate biomarkers related to the safety and efficacy of HM95573.

Eligibility criteria: Inclusion Criteria:

* Patients must be 20 years of age or older
* Subjects who have provided voluntary consent to participate in the study, and signed the written consent document.
* Estimated life expectancy of at least 12 weeks
* Histologically or cytologically confirmed advanced solid tumor

Exclusion Criteria:

* Symptomatic or uncontrolled central nervous system metastases
* Patients who are unable to take tablets orally or have a clinically significant gastrointestinal disorder, which may interfere with administration, metabolism and absorption of the investigational drug.
* Patients who, in the investigator's opinion, are not suitable for the study for any other reason.

Primary outcomes:
measure: Safety and tolerability
timeFrame: Dose limiting Toxicity will be evaluated on Day 28 during Cycle 1
Secondary outcomes:
measure: Overall rsponse rate
timeFrame: 6-12 weeks
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Hanmi Clinical
Study officials:
affiliation: Hanmi Pharmaceutical co., ltd.
name: Yohan Kim, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02520765: Obesity Index That Better Predict Ovarian Response
Official title: Obesity Index That Better Predict Ovarian Response: Body Mass Index, Waist Circumference, Waist Hip Ratio, or Waist Height Ratio in Women Undergoing ICSI
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Infertility
Keywords: Obesity Index, ICSI
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2015-08-13
Enrollment: 500
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 200 patients who are admitted to the IVF center at Ain Shmas University hospital and scheduled for ICSI

Brief summary: This study is designed to assess the accuracy of Body Mass Index ,Waist Circumference ,Waist Hip Ratio or Waist Height Ratio as a predictor of ovarian response in women undergoing ICSI.

Detailed description: Obesity is an increasingly serious health concern worldwide, and its association with many diseases has been demonstrated. Obesity as it relates to infertility is also being studied All these studies used body mass index (BMI) to determine obesity. Although it is the most commonly used parameter to measure obesity, BMI does not provide an accurate measure of a person's body composition, including body fat.

Almost all studies conducted on this subject used body mass index (BMI) as the measure of obesity; however, using only BMI might be the wrong strategy. Interestingly, some studies on the cardiovascular system found protective effects of BMI and as a result a new term, 'obesity paradox,' emerged. Later studies used waist-to-hip (W/H) ratio and wrist circumference (WC) as a measure of obesity, and showed the exact effect of body fat distribution and obesity on the cardiovascular system

Eligibility criteria: Inclusion Criteria:

* Patients scheduled for ICSI

Exclusion Criteria:

* Poor Responders.
* Poly cystic ovary syndrome.
* Previous ovarian surgeries.
* Patients with ovarian cysts
* patients with endometriosis
* women age more than 35 years

Primary outcomes:
measure: number of oocytes
timeFrame: 1 month
Secondary outcomes:
measure: clinical pregnancy rate
timeFrame: 7 Weeks
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Medicine, Ain Shams University
state: Al Qahirah
Study officials:
affiliation: Ain Shams University
name: Ahmed dr kotb, MD
role: PRINCIPAL_INVESTIGATOR
References: